About Questcor Pharmaceuticals (NASDAQ:QCOR)
Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. The Company is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Its primary product is H.P. Acthar Gel (repository corticotropin injection), or Acthar, an injectable drug that is approved by the United States food and drug administration (FDA), for the treatment of 19 indications. Its research and development program is focused on: the evaluation of the use of Acthar for certain on-label indications; the investigation of other potential uses of Acthar for indications not FDA approved; and the expansion of its understanding of how Acthar works in the human body (pharmacology), and ultimately, its mechanisms of action in the disease states for which it is used, or may be used in the future. The Company sells Doral to pharmaceutical wholesalers, which resell Doral primarily to retail pharmacies and hospitals.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Questcor Pharmaceuticals (NASDAQ:QCOR) Frequently Asked Questions
What is Questcor Pharmaceuticals' stock symbol?
Questcor Pharmaceuticals trades on the NASDAQ under the ticker symbol "QCOR."
Who are some of Questcor Pharmaceuticals' key competitors?
Some companies that are related to Questcor Pharmaceuticals include GlaxoSmithKline (GSK), AstraZeneca (AZN), Beximco Pharmaceuticals (BXP), Shire (SHP), Hikma Pharmaceuticals (HIK), BTG (BTG), CoLucid Pharmaceuticals (CLCD), SciClone Pharmaceuticals (SCLN), SkyePharma (SKP), Diurnal Group (DNL), Allergy Therapeutics (AGY), Innocoll (INNL), Aegerion Pharmaceuticals (AEGR), Amryt Pharma (AMYT), N4 Pharma (N4P), Venture Life Group (VLG), SLS International (SLS) and Avanir Pharmaceuticals (AVNR).
Has Questcor Pharmaceuticals been receiving favorable news coverage?
News coverage about QCOR stock has trended positive recently, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Questcor Pharmaceuticals earned a media sentiment score of 0.39 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 45.19 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Questcor Pharmaceuticals?
Shares of QCOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Questcor Pharmaceuticals?
Questcor Pharmaceuticals' mailing address is 1300 N Kellogg Dr Ste D, ANAHEIM, CA 92807-1965, United States. The biopharmaceutical company can be reached via phone at +1-714-7864200.
MarketBeat Community Rating for Questcor Pharmaceuticals (QCOR)MarketBeat's community ratings are surveys of what our community members think about Questcor Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Questcor Pharmaceuticals (NASDAQ:QCOR) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Questcor Pharmaceuticals (NASDAQ:QCOR) Earnings History and Estimates Chart
Questcor Pharmaceuticals (NASDAQ QCOR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/24/2014||Q214||$1.74||$1.85||$261.02 million||$278.80 million||View||N/A|
|4/28/2014||Q114||$1.61||$1.40||$239.81 million||$227.10 million||View||N/A|
|2/25/2014||Q413||$1.66||$1.67||$244.15 million||$243.00 million||View||N/A|
|10/29/2013||Q313||$1.29||$1.52||$199.70 million||$236.35 million||View||N/A|
|7/30/2013||Q2 2013||$0.96||$1.12||$168.96 million||$184.60 million||View||N/A|
|4/30/2013||Q1 2013||$0.96||$0.76||$157.68 million||$135.13 million||View||N/A|
|2/26/2013||Q4 2012||$0.90||$1.03||$142.58 million||$160.50 million||View||N/A|
Questcor Pharmaceuticals (NASDAQ:QCOR) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Questcor Pharmaceuticals (NASDAQ:QCOR) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Questcor Pharmaceuticals (NASDAQ QCOR) Insider Trading and Institutional Ownership History
Questcor Pharmaceuticals (NASDAQ QCOR) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/13/2014||Don M Bailey||Insider||Sell||40,000||$91.96||$3,678,400.00|| |
|8/11/2014||Michael H Mulroy||Insider||Sell||10,000||$92.33||$923,300.00|| |
|7/14/2014||Don M Bailey||Insider||Sell||40,000||$95.54||$3,821,600.00|| |
|7/10/2014||Michael H Mulroy||Insider||Sell||10,000||$90.89||$908,900.00|| |
|6/24/2014||David Young||Insider||Sell||6,000||$91.96||$551,760.00|| |
|6/13/2014||Don M Bailey||CEO||Sell||40,000||$89.83||$3,593,200.00|| |
|6/10/2014||Michael H Mulroy||Insider||Sell||10,000||$88.57||$885,700.00|| |
|5/19/2014||David Jeffrey Medeiros||EVP||Sell||2,292||$89.66||$205,500.72||120,039|| |
|5/13/2014||Don Bailey||CEO||Sell||40,000||$87.05||$3,482,000.00|| |
|5/12/2014||Michael Mulroy||Insider||Sell||10,000||$87.99||$879,900.00||77,063|| |
|4/21/2014||David Jeffrey Medeiros||EVP||Sell||2,292||$77.15||$176,827.80||120,039|| |
|4/14/2014||Don Bailey||CEO||Sell||40,000||$79.65||$3,186,000.00|| |
|4/10/2014||Michael Mulroy||Insider||Sell||10,000||$85.04||$850,400.00||77,063|| |
|4/7/2014||Stephen Farrell||Director||Sell||10,000||$81.43||$814,300.00||20,433|| |
|3/17/2014||David Jeffrey Medeiros||EVP||Sell||2,291||$62.61||$143,439.51||120,039|| |
|3/14/2014||David Young||Insider||Sell||6,000||$62.28||$373,680.00||111,741|| |
|3/13/2014||Don Bailey||CEO||Sell||40,000||$62.71||$2,508,400.00|| |
|3/10/2014||Michael Mulroy||Insider||Sell||10,000||$64.80||$648,000.00||77,063|| |
|2/25/2014||Broadwood Partners Lp||Director||Sell||83,600||$79.59||$6,653,724.00|| |
|2/20/2014||Broadwood Partners Lp||Director||Sell||306,400||$74.94||$22,961,616.00|| |
|2/12/2014||Broadwood Partners Lp||Director||Sell||85,000||$69.10||$5,873,500.00|| |
|1/30/2014||Broadwood Partners Lp||Director||Sell||50,000||$66.55||$3,327,500.00|| |
|1/24/2014||David Young||Insider||Sell||6,000||$64.38||$386,280.00||91,145|| |
|1/23/2014||Broadwood Partners Lp||Director||Sell||20,000||$65.00||$1,300,000.00|| |
|1/23/2014||David Jeffrey Medeiros||EVP||Sell||133,541||$64.91||$8,668,146.31||118,051|| |
|1/16/2014||David Jeffrey Medeiros||EVP||Sell||50,000||$62.00||$3,100,000.00||118,051|| |
|1/13/2014||Don Bailey||CEO||Sell||40,000||$53.64||$2,145,600.00|| |
|11/14/2013||Neal Bradsher||Director||Sell||40,000||$62.41||$2,496,400.00|| |
|11/13/2013||Broadwood Partners Lp||Director||Sell||500,000||$62.37||$31,185,000.00|| |
|10/14/2013||Don Bailey||CEO||Sell||40,000||$62.16||$2,486,400.00|| |
|10/14/2013||Virgil Thompson||Director||Sell||2,500||$60.50||$151,250.00||29,867|| |
|9/16/2013||Virgil Thompson||Director||Sell||5,000||$63.75||$318,750.00||29,867|| |
|9/13/2013||Don Bailey||CEO||Sell||40,000||$63.69||$2,547,600.00|| |
|8/26/2013||David Jeffrey Medeiros||EVP||Sell||55,000||$73.98||$4,068,900.00||117,121|| |
|8/14/2013||Virgil Thompson||Director||Sell||5,000||$69.12||$345,600.00||29,867|| |
|8/13/2013||David Jeffrey Medeiros||EVP||Sell||110,597||$67.85||$7,504,006.45||117,121|| |
|8/6/2013||David Jeffrey Medeiros||EVP||Sell||58,831||$66.69||$3,923,439.39||117,121|| |
|7/15/2013||Don M Bailey||CEO||Sell||33,339||$49.31||$1,643,946.09|| |
|7/15/2013||Virgil D Thompson||Director||Sell||5,000||$49.29||$246,450.00|| |
|6/14/2013||Virgil D Thompson||Director||Sell||5,000||$45.55||$227,750.00|| |
|6/13/2013||Don M Bailey||CEO||Sell||40,000||$45.01||$1,800,400.00|| |
|5/14/2013||Don M Bailey||CEO||Sell||180,000||$40.14||$7,225,200.00|| |
|5/14/2013||Virgil D Thompson||Director||Sell||5,000||$37.46||$187,300.00|| |
|5/9/2013||Virgil D Thompson||Director||Sell||2,187||$35.00||$76,545.00|| |
|3/21/2013||Virgil D Thompson||Director||Sell||47,500||$35.00||$1,662,500.00|| |
|11/5/2012||David Jeffrey Medeiros||EVP||Buy||55,000||$23.92||$1,315,600.00|| |
|11/2/2012||Stephen Lahue Cartt||VP||Buy||10,000||$24.17||$241,700.00|| |
|9/4/2012||Mitchell J Md Blutt||Director||Sell||24,730||$47.60||$1,177,148.00|| |
Questcor Pharmaceuticals (NASDAQ QCOR) News Headlines
Questcor Pharmaceuticals (NASDAQ:QCOR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Questcor Pharmaceuticals (NASDAQ:QCOR) Income Statement, Balance Sheet and Cash Flow Statement
Questcor Pharmaceuticals (NASDAQ QCOR) Stock Chart for Wednesday, March, 21, 2018